Development and in-vitro evaluation of chitosan chloridedecorated PLGA based polymeric nanoparticles ofnimesulide

The aim of this study is to develop PLGA based nanoparticle drug delivery systems loaded with nimesulide which is a non-steroidal anti-inflammatory (NSAI) agent and a selective COX-2 inhibitor that proved its antineoplastic and antitumor activity on cancer carsinogenesis and chemotherapy via epidemiological, pathological, clinical and biological studies in the last years, and modify their surface properties using chitosan chloride. For this purpose, Nimesulide loaded PLGA nanoparticles modified with chitosan chloride were developed with solvent evaporation-diffusion-salting out method. Nanoparticle formulations were evaluated for production yield, process efficacy, particle size and polydispersity index (PDI), surface charge, morphologic properties, redispersibility index, residual PVA amount and in vitro dissolution rate profiles. The results obtained showed that surface modification with chitosan chloride was significantly effective statistically on the final properties of the nanoparticles. With this study, it was shown that PVA and chitosan chloride combined can play a key role in developing cationic and positively charged nanoparticles.

PDF

___

[1] Shuangshuang L, Min J, Lu W, Shuwen Y. Combined chemotherapy with cyclooxygenase-2 (COX-2) inhibitors in treating human cancers: Recent advancement. Biomed Pharmacother. 2020; 129: 110389. [CrossRef]
[2] Regulski M, Regulska K, Prukała W, Piotrowska H, Stanisz B, Murias M. COX-2 inhibitors: a novel strategy in the management of breast cancer. Drug Discov Today. 2016; 21 (4): 598-615. [CrossRef]
[3] Sengel-Turk CT, Hascicek C, Bakar F, Simsek E. Comparative evaluation of nimesulide-loaded nanoparticles for anticancer activity against breast cancer cells. AAPS. 2017; 18(2): 393-403. [CrossRef]
[4] Tian J, Guo F, Chen Y, Li Y, Yu B, Li Y. Nanoliposomal formulation encapsulating celecoxib and genistein inhibiting COX-2 pathway and Glut-1 receptors to prevent prostate cancer cell proliferation. Cancer Lett. 2019; 448: 1-10. [CrossRef]
[5] Wusiman A, Jiang W, Yu L, Zhu T, He J, Liu Z, Bo R, Liu J, Wang D. Cationic polymer-modified Alhagi honey polysaccharide PLGA nanoparticles as an adjuvant to induce strong and long-lasting immune responses. Int J Biol Macromol. 2021; 177: 370-382. [CrossRef]
[6] Wusiman A, He J, Zhu T, Liu Z, Gu P, Hu Y, Liu J, Wang D. Macrophage immunomodulatory activity of the cationic polymer modified PLGA nanoparticles encapsulating Alhagi honey polysaccharide. Int J Biol Macromol. 2019; 134: 730-739. [CrossRef]
[7] Choi JS, Park JS. Design and evaluation of the anticancer activity of paclitaxel-loaded anisotropic-poly(lactic-coglycolic acid) nanoparticles with PEGylated chitosan surface modifications. Int J Biol Macromol. 2020; 162: 1064-1075. [CrossRef]
[8] Yurtdaş-Kırımlıoğlu G, Görgülü Ş. Surface modification of PLGA nanoparticles with chitosan or Eudragit® RS 100: Characterization, prolonged release, cytotoxicity, and enhanced antimicrobial activity. J Drug Delivery Sci Technol. 2021; 61: 102145. [CrossRef]
[9] Chen H, Xi LQ, Qin J, Jia Y, Cai X, Nan WB, Yang W, Lv F, Zhang QQ. Surface modification of PLGA nanoparticles with biotinylated chitosan for the sustained in vitro release and the enhanced cytotoxicity of epirubicin. Coll Surf B Biointerfaces. 2016; 138: 1-9. [CrossRef]
[10] Sengel-Turk CT, Hascicek C, Dogan AL, Esendagli G, Guc D, Gonul N. Surface modification and evaluation of PLGA nanoparticles: the effects on cellular uptake and cell proliferation on the HT-29 cell line. J Drug Delivery Sci Technol. 2014; 24(2): 166-172. [CrossRef]
[11] Esmaeili F, Ghahremani MH, Esmaeili B, Khoshayand MR, Atyabi F, Dinarvand R. PLGA nanoparticles of different surface properties: preparation and evaluation of their body distribution. Int J Pharm. 2008; 349(1-2): 249-55. [CrossRef]
[12] Babya T, Liu Y, Yang G, Chen D, Zhao CX. Microfluidic synthesis of curcumin loaded polymer nanoparticles with tunable drug loading and pH-triggered release. J Colloid Interface Sci. 2021; 594: 474-484. [CrossRef]
[13] Sengel-Turk CT, Ozmen N, Bakar-Ates F. Design, characterization and evaluation of cucurbitacin B loaded core-shell type hybrid nano-sized particles using DoE approach. Polym Bull. 2021; 78(6): 3327-3351. [CrossRef]
[14] Nafee N, Taetz S, Schneider M, Schaefer UF, Lehr CM. Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: effect of the formulation parameters on complexation and transfection of antisense oligonucleotides. Nanomedicine. 2007; 3(3):173-183. [CrossRef]
[15] Escareño N, Hassan N, Kogan MJ, Juárez J, Topete A, Daneri-Navarro A. Microfluidics-assisted conjugation of chitosan-coated polymeric nanoparticles with antibodies: Significance in drug release, uptake, and cytotoxicity in breast cancer cells. J Colloid Interface Sci. 2021; 591: 440-450. [CrossRef]
[16] Sahoo SK, Panyam J, Prabha S, Labhasetwar V. Residual polyvinyl alcohol associated with poly (D,L-lactide-coglycolide) nanoparticles affects their physical properties and cellular uptake. J Control Release 2002; 82(1):105-114. [CrossRef]
[17] Ahmad N, Ahmad R, Alam MA, Ahmad FJ, Amir M, Pottoo FH, Sarafroz M, Jafar M, Umar K. Daunorubicin oral bioavailability enhancement by surface coated natural biodegradable macromolecule chitosan based polymeric nanoparticles. Int J Biol Macromol. 2019; 128: 825-838. [CrossRef]
[18] Chakravarthi SS, Robinson DH. Nanoparticles prepared using natural and synthetic polymers. In: Thassu D, Deleers M, Pathak Y. (Eds). Nanoparticulate Drug Delivery Systems, Informa Healthcare, New York, 2007, pp. 51-60.
[19] Stauch C, Späth S, Ballweg T, Luxenhofer R, Mandel K. Nanostructured micro-raspberries from superparamagnetic iron oxide nanoparticles: Studying agglomeration degree and redispersibility of nanoparticulate powders via magnetisation measurements. J Colloid Interface Sci 2017; 505: 605-614. [CrossRef]
[20] Bakar-Ates F, Ozkan E, Sengel-Turk CT. Encapsulation of cucurbitacin B into lipid polymer hybrid nanocarriers induced apoptosis of MDAMB231 cells through PARP cleavage. Int J Pharm. 2020; 586: 119565. [CrossRef]
[21] Patel G, Thakur NS, Kushwah V, Patil MD, Nile SH, Jain S, Kai G, Banerjee UC. Mycophenolate co-administration with quercetinvialipid-polymer hybridnanoparticles for enhanced breast cancer management. Nanomedicine. 2020; 24: 102147. [CrossRef]
[22] Lee SC, Oh JT, Jang MH, Chung SI. Quantitative analysis of polyvinyl alcohol on the surface of poly(D, L-lactide-coglycolide) microparticles prepared by solvent evaporation method: effect of particle size and PVA concentration. J Control Release. 1999; 59(2): 123-132. [CrossRef]
[23] Hejazi R, Amiji M. Chitosan-based gastrointestinal delivery systems. J Control Release. 2003; 89(2):151-165. [CrossRef]
[24] Sengel-Turk CT, Hascicek C, Dogan AL, Esendagli G, Guc D, Gonol N. Preparation and in vitro evaluation of meloxicam-loaded PLGA nanoparticles on HT-29 human colon adenocarcinoma cells. Drug Dev Ind Pharm. 2012; 38(9): 1107-1116. [CrossRef]
[25] Sengel-Turk CT, Hascicek C., Gonul N. Microsphere-based once-daily modified release matrix tablets for oral administration in angina pectoris. J Microencapsul. 2008; 25(4): 257-266. [CrossRef]
[26] Sengel-Turk CT, Hascicek C, Gonul N. Ethylcellulose-Based Matrix-Type Microspheres: Influence of Plasticizer Ratio as Pore-Forming Agent. AAPS PharmSciTech. 2011; 12(4): 1127-1135. [CrossRef]
[27] Turk CTS, Oz UC, Serim TM, Hascicek C. Formulation and optimization of nonionic surfactants emulsified nimesulide-loaded PLGA-based nanoparticles by design of experiments. AAPS PharmSciTech. 2014; 15(1): 161-176. [CrossRef]
[28] ICH Q1Q (R2) (2003). Stability testing of new drug substances and products, ICH Harmonised Tripartite Guideline. https://www.ich.org/page/quality-guidelines (accessed on 12 April 2021).